| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
|
Clin Infect Dis
|
2007
|
2.19
|
|
2
|
A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP).
|
Pediatr Blood Cancer
|
2007
|
2.15
|
|
3
|
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
|
Lancet Neurol
|
2010
|
2.03
|
|
4
|
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?
|
Brain
|
2007
|
1.94
|
|
5
|
Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration.
|
Ann Neurol
|
2003
|
1.88
|
|
6
|
Neurological deficits caused by tissue hypoxia in neuroinflammatory disease.
|
Ann Neurol
|
2013
|
1.70
|
|
7
|
Axonal protection using flecainide in experimental autoimmune encephalomyelitis.
|
Ann Neurol
|
2004
|
1.68
|
|
8
|
Economics of influenza vaccine administration timing for children.
|
Am J Manag Care
|
2010
|
1.65
|
|
9
|
Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
|
Infect Control Hosp Epidemiol
|
2008
|
1.61
|
|
10
|
Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide.
|
Brain
|
2004
|
1.60
|
|
11
|
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
|
Brain
|
2013
|
1.53
|
|
12
|
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
|
Pharmacoeconomics
|
2010
|
1.46
|
|
13
|
A cost-effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children.
|
Pediatr Blood Cancer
|
2010
|
1.44
|
|
14
|
Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
|
Am J Kidney Dis
|
2012
|
1.44
|
|
15
|
The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure.
|
J Ment Health Policy Econ
|
2012
|
1.42
|
|
16
|
Neuroprotection and repair in multiple sclerosis.
|
Nat Rev Neurol
|
2012
|
1.41
|
|
17
|
InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence: A Decision Analysis Comparing Outcomes Including Efficacy and Complications.
|
Female Pelvic Med Reconstr Surg
|
2011
|
1.38
|
|
18
|
Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination.
|
Acta Neuropathol
|
2010
|
1.37
|
|
19
|
Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide.
|
Brain
|
2005
|
1.26
|
|
20
|
Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies.
|
J Clin Endocrinol Metab
|
2012
|
1.24
|
|
21
|
The timing of influenza vaccination for older adults (65 years and older).
|
Vaccine
|
2009
|
1.21
|
|
22
|
Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza.
|
Vaccine
|
2010
|
1.19
|
|
23
|
Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults.
|
J Gen Intern Med
|
2014
|
1.17
|
|
24
|
To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling.
|
PLoS One
|
2010
|
1.13
|
|
25
|
Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis.
|
Infect Control Hosp Epidemiol
|
2010
|
1.09
|
|
26
|
Forecasting the economic value of an Enterovirus 71 (EV71) vaccine.
|
Vaccine
|
2010
|
1.07
|
|
27
|
High resolution (13)C MRI with hyperpolarized urea: in vivo T(2) mapping and (15)N labeling effects.
|
IEEE Trans Med Imaging
|
2013
|
1.05
|
|
28
|
Axonal protection achieved in a model of multiple sclerosis using lamotrigine.
|
J Neurol
|
2006
|
0.98
|
|
29
|
Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism.
|
Chest
|
2005
|
0.96
|
|
30
|
Remyelination of dorsal column axons by endogenous Schwann cells restores the normal pattern of Nav1.6 and Kv1.2 at nodes of Ranvier.
|
Brain
|
2006
|
0.95
|
|
31
|
Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma.
|
J Magn Reson Imaging
|
2011
|
0.95
|
|
32
|
Prediction of pelvic inflammatory disease among young, single, sexually active women.
|
Sex Transm Dis
|
2006
|
0.94
|
|
33
|
A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population.
|
Vaccine
|
2009
|
0.92
|
|
34
|
The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: evidence from a Markov model.
|
J Urol
|
2011
|
0.91
|
|
35
|
The potential economic value of a hookworm vaccine.
|
Vaccine
|
2010
|
0.91
|
|
36
|
Economic model for emergency use authorization of intravenous peramivir.
|
Am J Manag Care
|
2011
|
0.89
|
|
37
|
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
|
Gynecol Oncol
|
2011
|
0.89
|
|
38
|
Cost-effectiveness of implementing the chronic care model for diabetes care in a military population.
|
J Diabetes Sci Technol
|
2011
|
0.89
|
|
39
|
Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
|
Thromb Res
|
2013
|
0.88
|
|
40
|
Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups.
|
Vaccine
|
2011
|
0.88
|
|
41
|
Sodium-mediated axonal degeneration in inflammatory demyelinating disease.
|
J Neurol Sci
|
2005
|
0.88
|
|
42
|
Retropubic and transobturator midurethral slings: a decision analysis to compare outcomes including efficacy and complications.
|
Int Urogynecol J
|
2010
|
0.87
|
|
43
|
Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis.
|
Int Urogynecol J Pelvic Floor Dysfunct
|
2009
|
0.86
|
|
44
|
Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus?
|
Infect Control Hosp Epidemiol
|
2009
|
0.86
|
|
45
|
Contraceptive effectiveness of immediate compared with delayed insertion of intrauterine devices after abortion: a decision analysis.
|
Obstet Gynecol
|
2007
|
0.86
|
|
46
|
MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.
|
Neuro Oncol
|
2011
|
0.83
|
|
47
|
Screening cardiac surgery patients for MRSA: an economic computer model.
|
Am J Manag Care
|
2010
|
0.83
|
|
48
|
The potential economic value of a Staphylococcus aureus vaccine for neonates.
|
Vaccine
|
2010
|
0.82
|
|
49
|
Reliability of laparoscopic compared with hysteroscopic sterilization at 1 year: a decision analysis.
|
Obstet Gynecol
|
2011
|
0.82
|
|
50
|
Cost-effectiveness of endoscopic sphenopalatine artery ligation versus nasal packing as first-line treatment for posterior epistaxis.
|
Int Forum Allergy Rhinol
|
2013
|
0.81
|
|
51
|
Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model.
|
Alcohol Clin Exp Res
|
2009
|
0.81
|
|
52
|
The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: a Markov decision analysis approach.
|
Laryngoscope
|
2011
|
0.81
|
|
53
|
A cost-effectiveness analysis of positron emission tomography-computed tomography surveillance versus up-front neck dissection for management of the neck for N2 disease after chemoradiotherapy.
|
Laryngoscope
|
2012
|
0.81
|
|
54
|
Cost-effectiveness of implantable cardioverter-defibrillators in children with dilated cardiomyopathy.
|
J Card Fail
|
2010
|
0.81
|
|
55
|
FDA warning and removal of rosiglitazone from VA national formulary.
|
Am J Manag Care
|
2013
|
0.81
|
|
56
|
Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients.
|
J Vasc Surg
|
2010
|
0.81
|
|
57
|
Managing mesh exposure following vaginal prolapse repair: a decision analysis comparing conservative versus surgical treatment.
|
Int Urogynecol J
|
2012
|
0.81
|
|
58
|
Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis.
|
Value Health
|
2013
|
0.80
|
|
59
|
Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective.
|
Thromb Haemost
|
2012
|
0.79
|
|
60
|
Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
|
Am J Manag Care
|
2013
|
0.79
|
|
61
|
Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation.
|
PLoS One
|
2012
|
0.79
|
|
62
|
Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
|
Am J Med
|
2005
|
0.78
|
|
63
|
Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.
|
CNS Drugs
|
2010
|
0.78
|
|
64
|
Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States.
|
BMC Public Health
|
2014
|
0.77
|
|
65
|
Using thrombophilia testing to determine anticoagulation duration in pediatric thrombosis is not cost-effective.
|
J Pediatr
|
2009
|
0.77
|
|
66
|
Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.
|
Thromb Res
|
2013
|
0.76
|
|
67
|
Axonal morphological changes following impulse activity in mouse peripheral nerve in vivo: the return pathway for sodium ions.
|
J Physiol
|
2015
|
0.76
|
|
68
|
Microtomographic analysis of lower urinary tract obstruction.
|
Pediatr Dev Pathol
|
2013
|
0.76
|
|
69
|
Cognitive-affective resilience indicia as predictors of burnout and job-related outcome.
|
Int J Emerg Ment Health
|
2008
|
0.76
|
|
70
|
The role of CD8(+) T cells in a model of multiple sclerosis induced with recombinant myelin oligodendrocyte glycoprotein.
|
Mult Scler
|
2011
|
0.75
|
|
71
|
Probability of pregnancy after sterilization: a comparison of hysteroscopic versus laparoscopic sterilization.
|
Contraception
|
2015
|
0.75
|
|
72
|
Herpes zoster vaccine and older adults.
|
JAMA
|
2011
|
0.75
|
|
73
|
Optimal approach to improving trauma triage decisions: a cost-effectiveness analysis.
|
Am J Manag Care
|
2012
|
0.75
|
|
74
|
Brain-derived neurotrophic factor in experimental autoimmune neuritis.
|
J Neuroimmunol
|
2002
|
0.75
|
|
75
|
Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.
|
Am J Epidemiol
|
2017
|
0.75
|
|
76
|
Axonal protection achieved by blockade of sodium/calcium exchange in a new model of ischemia in vivo.
|
Neuropharmacology
|
2012
|
0.75
|
|
77
|
Cost-effectiveness of transoral robotic surgery in the unknown primary: corrigendum and response to comments.
|
Otolaryngol Head Neck Surg
|
2014
|
0.75
|
|
78
|
Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
|
Thromb Haemost
|
2005
|
0.75
|
|
79
|
Cost-identification analysis of total laryngectomy: an itemized approach to hospital costs.
|
Otolaryngol Head Neck Surg
|
2011
|
0.75
|
|
80
|
A multispectral microscope for in vivo oximetry of rat dorsal spinal cord vasculature.
|
Physiol Meas
|
2016
|
0.75
|
|
81
|
Three cost-utility analyses of screening for intracranial hemorrhage in neonates with hemophilia.
|
J Pediatr Hematol Oncol
|
2014
|
0.75
|
|
82
|
Incremental cost-effectiveness of various monthly doses of vardenafil.
|
Value Health
|
2011
|
0.75
|
|
83
|
Cost-effectiveness of a statewide falls prevention program in Pennsylvania: Healthy Steps for Older Adults.
|
Am J Manag Care
|
2016
|
0.75
|
|
84
|
Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia.
|
J Pediatr
|
2010
|
0.75
|
|
85
|
A rationale for cognitively-based resilience and psychological first aid (PFA) training: a structural modeling analysis.
|
Int J Emerg Ment Health
|
2009
|
0.75
|
|
86
|
Promoting Organ Donor Registries Through Public Education: What Is the Cost of Securing Organ Donors?
|
Transplantation
|
2016
|
0.75
|
|
87
|
A defining aspect of human resilience in the workplace: a structural modeling approach.
|
Disaster Med Public Health Prep
|
2011
|
0.75
|
|
88
|
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
|
Transfusion
|
2007
|
0.75
|
|
89
|
Lamotrigine monotherapy does not provide protection against the loss of optic nerve axons in a rat model of ocular hypertension.
|
Exp Eye Res
|
2012
|
0.75
|
|
90
|
Direct paramedic transport of acute myocardial infarction patients to percutaneous coronary intervention centers: a decision analysis.
|
Ann Emerg Med
|
2008
|
0.75
|
|
91
|
Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage.
|
Anesthesiology
|
2017
|
0.75
|
|
92
|
High-Value Consults: A Curriculum to Promote Point-of-Care, Evidence-Based Recommendations.
|
J Grad Med Educ
|
2017
|
0.75
|
|
93
|
Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.
|
Oncol Res
|
2015
|
0.75
|
|
94
|
Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.
|
Appl Health Econ Health Policy
|
2013
|
0.75
|
|
95
|
Synchrotron Photoionization Study of Furan and 2-Methylfuran Reactions with Methylidyne Radical (CH) at 298 K.
|
J Phys Chem A
|
2017
|
0.75
|